Subependymal giant cell astrocytoma secondary prevention: Difference between revisions
Jump to navigation
Jump to search
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Effective measures for the secondary prevention of subependymal giant cell astrocytoma include brain imaging, preferably [[MRI|magnetic resonance imaging]] with and without contrast, which should be performed every 1 to 3 years until the age of 25 years in every patient with [[tuberous sclerosis]]. | Effective measures for the [[secondary prevention]] of subependymal giant cell astrocytoma include [[brain imaging]], preferably [[MRI|magnetic resonance imaging]] with and without [[Contrast medium|contrast]], which should be performed every 1 to 3 years until the age of 25 years in every patient with [[tuberous sclerosis]]. | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
Effective measures for the secondary prevention of subependymal giant cell astrocytoma include:<ref name="RothRoach2013">{{cite journal|last1=Roth|first1=Jonathan|last2=Roach|first2=E. Steve|last3=Bartels|first3=Ute|last4=Jóźwiak|first4=Sergiusz|last5=Koenig|first5=Mary Kay|last6=Weiner|first6=Howard L.|last7=Franz|first7=David N.|last8=Wang|first8=Henry Z.|title=Subependymal Giant Cell Astrocytoma: Diagnosis, Screening, and Treatment. Recommendations From the International Tuberous Sclerosis Complex Consensus Conference 2012|journal=Pediatric Neurology|volume=49|issue=6|year=2013|pages=439–444|issn=08878994|doi=10.1016/j.pediatrneurol.2013.08.017}}</ref> | Effective measures for the secondary prevention of subependymal giant cell astrocytoma include:<ref name="RothRoach2013">{{cite journal|last1=Roth|first1=Jonathan|last2=Roach|first2=E. Steve|last3=Bartels|first3=Ute|last4=Jóźwiak|first4=Sergiusz|last5=Koenig|first5=Mary Kay|last6=Weiner|first6=Howard L.|last7=Franz|first7=David N.|last8=Wang|first8=Henry Z.|title=Subependymal Giant Cell Astrocytoma: Diagnosis, Screening, and Treatment. Recommendations From the International Tuberous Sclerosis Complex Consensus Conference 2012|journal=Pediatric Neurology|volume=49|issue=6|year=2013|pages=439–444|issn=08878994|doi=10.1016/j.pediatrneurol.2013.08.017}}</ref> | ||
*Brain imaging, preferably [[MRI|magnetic resonance imaging]] with and without contrast, should be performed every 1 to 3 years until the age of 25 years in every patient with [[tuberous sclerosis]]. | *[[Brain imaging]], preferably [[MRI|magnetic resonance imaging]] with and without [[Contrast medium|contrast]], should be performed every 1 to 3 years until the age of 25 years in every patient with [[tuberous sclerosis]]. | ||
*Follow-up [[MRI|magnetic resonance imaging]] may not be needed every 3 years, but intervals may be prolonged in the presence of a stable lesion and a stable patient. | *Follow-up [[MRI|magnetic resonance imaging]] may not be needed every 3 years, but intervals may be prolonged in the presence of a stable [[lesion]] and a stable patient. | ||
*Screening and follow-up scans frequency should be tailored according to various clinical factors. | *Screening and follow-up scans frequency should be tailored according to various clinical factors. | ||
:*New onset of symptoms such as [[headache]], [[visual loss|visual complaints]], [[nausea]], [[vomiting]], or increase in [[seizure|seizure activity]] should warrant an earlier MRI scan. | |||
:*New onset of [[Symptom|symptoms]] such as [[headache]], [[visual loss|visual complaints]], [[nausea]], [[vomiting]], or increase in [[seizure|seizure activity]] should warrant an earlier [[MRI]] scan. | |||
:*Similarly, a growing subependymal giant cell astrocytoma should prompt a more frequent clinical and radiological follow-up. | :*Similarly, a growing subependymal giant cell astrocytoma should prompt a more frequent clinical and radiological follow-up. | ||
Revision as of 14:23, 7 November 2019
|
Subependymal giant cell astrocytoma Microchapters |
|
Differentiating Subependymal Giant Cell Astrocytoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Subependymal giant cell astrocytoma secondary prevention On the Web |
|
American Roentgen Ray Society Images of Subependymal giant cell astrocytoma secondary prevention |
|
FDA on Subependymal giant cell astrocytoma secondary prevention |
|
CDC on Subependymal giant cell astrocytoma secondary prevention |
|
Subependymal giant cell astrocytoma secondary prevention in the news |
|
Blogs on Subependymal giant cell astrocytoma secondary prevention |
|
Risk calculators and risk factors for Subependymal giant cell astrocytoma secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
Effective measures for the secondary prevention of subependymal giant cell astrocytoma include brain imaging, preferably magnetic resonance imaging with and without contrast, which should be performed every 1 to 3 years until the age of 25 years in every patient with tuberous sclerosis.
Secondary Prevention
Effective measures for the secondary prevention of subependymal giant cell astrocytoma include:[1]
- Brain imaging, preferably magnetic resonance imaging with and without contrast, should be performed every 1 to 3 years until the age of 25 years in every patient with tuberous sclerosis.
- Follow-up magnetic resonance imaging may not be needed every 3 years, but intervals may be prolonged in the presence of a stable lesion and a stable patient.
- Screening and follow-up scans frequency should be tailored according to various clinical factors.
- New onset of symptoms such as headache, visual complaints, nausea, vomiting, or increase in seizure activity should warrant an earlier MRI scan.
- Similarly, a growing subependymal giant cell astrocytoma should prompt a more frequent clinical and radiological follow-up.
References
- ↑ Roth, Jonathan; Roach, E. Steve; Bartels, Ute; Jóźwiak, Sergiusz; Koenig, Mary Kay; Weiner, Howard L.; Franz, David N.; Wang, Henry Z. (2013). "Subependymal Giant Cell Astrocytoma: Diagnosis, Screening, and Treatment. Recommendations From the International Tuberous Sclerosis Complex Consensus Conference 2012". Pediatric Neurology. 49 (6): 439–444. doi:10.1016/j.pediatrneurol.2013.08.017. ISSN 0887-8994.